NLG802 (indoximod Prodrug)

DRUG2 trials

Sponsors

Luke, Jason, MD, Lumos Pharma

Conditions

Advanced Solid TumorsProgressive Pediatric Brain Cancer

Phase 1

Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors

WithdrawnNCT05469490

Luke, Jason, MDAdvanced Solid Tumors

Start: 2022-10-31End: 2026-12-31Updated: 2022-09-30

Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer

Not yet recruitingNCT07732413

Lumos PharmaProgressive Pediatric Brain Cancer

Start: 2026-10-08End: 2030-10-08Target: 30Updated: 2026-07-28